Commercial Printing

With the major indices starting off March with a bang Monday, there were plenty of stocks which traded higher on above average volume. If this is your first time reading one of my breakout reports you'll want to read the section below, however if you are familiar with my daily breakout report you...

For Immediate Release Chicago, IL – March 2, 2010 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Biogen...

The US Food and Drug Administration (FDA) recently issued a notice on its website regarding the risk of developing progressive multifocal leukoencephalopathy (PML) with increased use of Tysabri. Tysabri, which is marketed by Biogen Idec (BIIB) and Elan Corp. (ELN), is approved in the U.S. for the...

Analysts at Morgan Joseph upgrade Innerworkings (NASDAQ: INWK) from "hold" to "buy." According to Morgan Joseph, the upgrade in the rating was based on market share opportunities. INWK’s shares closed at $5.28 yesterday. More Analyst Ratings here

Bowne & Co., Inc. (NYSE: BNE) agreed to be acquired by R.R. Donnelley & Sons Co. (NASDAQ: RRD) for about $481 million in cash. R.R. Donnelley's offer values Bowne & Co. shares at $11.50, a 65% premium over the BNE’s closing price of $6.97 in the previous trading session. As a result,...

R.R. Donnelley (NYSE: RRD), the printing services provider, will acquire Bowne & Co. for $481 million in cash. The offer values Bowne & Co. shares at $11.50, a 65% to Tuesday's closing price. Bowne providers marketing communicatins and shareholder services. R.R. Donnelley said the...

In a major setback for Johnson & Johnson (JNJ), the company has decided to return global rights of ceftobiprole to its Swiss partner, Basilea Pharmaceuticals. The decision was taken following rejection of the marketing application for the drug in Europe.   The European Committee for Medicinal...

Recently, Merck & Co. Inc. (MRK) received approval from the European Commission (EC) for its fertility drug Elonva (corifollitropin alfa injection). The drug will be used as a treatment in controlled ovarian stimulation (COS) coupled with a GnRH antagonist for the development of multiple...

Deluxe Corporation (NYSE: DLX) shares closed in on their 52 week high of $18.11 when the shares climbed over 10%, trading at a daily high of $17.85 before ending the day at $17.71. Earnings per share were 59 cents on net income of $30.5 million in the 4th quarter 2009, compared to 54 cents per...

Last week, the European Medicines Agency (EMEA) finalized a review of Biogen Idec’s (BIIB) Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML) associated with the prolonged use of the drug. PML is a rare brain infection caused by the JC virus. The agency’s...

Last week, GlaxoSmithKline (GSK) and Denmark-based Genmab received good news with the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion for Arzerra (ofatumumab), a monoclonal antibody. GlaxoSmithKline is seeking approval for the use...

GlaxoSmithKline (GSK) recently received good news with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion for its oral thrombopoetin agonist, Revolade (eltrombopag). Glaxo is seeking approval for the use of Revolade as an oral treatment...

Below are the top 5 small-cap consumer goods stocks on the NASDAQ and the NYSE in terms of revenue estimates. The revenue estimate for Cenveo Inc (NASDAQ: CVO) for this year is $11.76 billion. CVO’s market capitalization is $553.2 million. CVO has trailing-twelve-month operating cash flows of $93....

Shire Plc (SHPGY) recently submitted a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) for Replagal (agalsidase alfa) meant for treating the genetic disorder Fabry disease.  Replagal is available in European markets since 2001.The drug is approved for the...